糖尿病视网膜病变（Diabetic Retinopathy, DR）是重要的致盲眼病，在其发展过程中，视网膜新生血管的产生是导致失明的重要原因。因此，抑制糖尿病视网膜新生血管的研究具有重要理论和临床意义。目前研究发现，转甲状腺素蛋白（Transthyretin，TTR）可以对人脐静脉血管内皮细胞的增殖及迁移有一定的抑制作用。申请人前期实验提示TTR对人视网膜微血管内皮细胞的增殖有抑制作用，但作用靶点及机制尚不清楚。本研究拟在体内体外实验中，解析TTR与DR视网膜新生血管生成的关系，分析病理条件下TTR结构和功能的变化；研究TTR对血管内皮细胞增殖和迁移的影响，并进一步利用分子生物学，免疫学等手段探索TTR抑制新生血管生成的作用靶点，揭示其作用机制。为DR发病机制的研究提供新线索，为有效控制DR视网膜新生血管的形成提供新思路。

Diabetic Retinopathy (DR) is an important ocular diseases leading to blindness; and in the development of DR, retinal neovascularization should be one of the most vital cause of blindness. Therefore, to research the inhibition of retinal neovascularization in DR is of great significance in both of theoretical and clinical fields. It has been reported that TTR could inhibit the proliferation and migration of human umbilical vein endothelial cells (HUVECs). And in our previous work, TTR could significantly reduce the proliferation rate of human retinal microvascular endothelial cells (hRECs), but the molecular mechanism is still unclear. In this research, the relationship between TTR and angiogenesis, the functional and structural diversification of TTR under pathological conditions, and the effects of TTR on the proliferation and migration of hRECs should be studied in vivo and in vitro. Furthermore, with molecular and immunological methods, the target site of TTR for inhibition of retinal neovascular would be reflected. This work is to reveal the inhibition mechanism of TTR against retinal neovascular of DR, and to provide theoretical basis for the rational therapy of DR.